Literature DB >> 28218043

UHRF1: The key regulator of epigenetics and molecular target for cancer therapeutics.

Harsimran Sidhu1, Neena Capalash1.   

Abstract

UHRF1 is a master regulator of epigenome as it coordinates DNA methylation and histone modifications. Compelling evidence suggests a strong link between UHRF1 overexpression and tumorigenesis, substantiating its ability to act as a potential biomarker for cancer diagnosis and prognosis. UHRF1 also mediates repair of damaged DNA that makes cancer cells resistant toward cytocidal drugs. Hence, understanding the molecular mechanism of UHRF1 regulation would help in developing cancer therapeutics. Natural compounds have shown applicability to downregulate UHRF1 leading to growth arrest and apoptosis in cancer cells.

Entities:  

Keywords:  UHRF1; biomarker; epigenetics; molecular regulation; natural polyphenols; resistance

Mesh：

Substances：

Year:  2017        PMID： 28218043     DOI： 10.1177/1010428317692205

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  31 in total

1.  Developmental and hormonal regulation of ubiquitin-like with plant homeodomain and really interesting new gene finger domains 1 gene expression in ovarian granulosa and theca cells of cattle.

Authors:  Maria Chiara Perego; Breanne C Morrell; Lingna Zhang; Luis F Schütz; Leon J Spicer
Journal:  J Anim Sci       Date:  2020-07-01       Impact factor: 3.159

Review 2.  Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Diagn Progn       Date:  2021-07-03

3.  Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression.

Authors:  Min Huang; Jasmine Zeki; Nathan Sumarsono; Garry L Coles; Jordan S Taylor; Enrico Danzer; Matias Bruzoni; Florette K Hazard; Norman J Lacayo; Kathleen M Sakamoto; James C Y Dunn; Sheri L Spunt; Bill Chiu
Journal:  Cancer Res       Date:  2020-01-03       Impact factor: 12.701

Review 4.  Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Authors:  Omeima Abdullah; Ziad Omran; Salman Hosawi; Ali Hamiche; Christian Bronner; Mahmoud Alhosin
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

5.  Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma.

Authors:  Alexander Beck; Franziska Trippel; Alexandra Wagner; Saskia Joppien; Max Felle; Christian Vokuhl; Thomas Schwarzmayr; Tim M Strom; Dietrich von Schweinitz; Gernot Längst; Roland Kappler
Journal:  Clin Epigenetics       Date:  2018-03-02       Impact factor: 6.551

6.  Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Authors:  Yahya I Elshimali; Yong Wu; Hussein Khaddour; Yanyuan Wu; Daniela Gradinaru; Hema Sukhija; Seyung S Chung; Jaydutt V Vadgama
Journal:  J Cancer Res Oncobiol       Date:  2018-02-27

7.  UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

Authors:  Emily S Reardon; Vivek Shukla; Sichuan Xi; Sudheer K Gara; Yi Liu; David Straughan; Mary Zhang; Julie A Hong; Eden C Payabyab; Anju Kumari; William G Richards; Assunta De Rienzo; Raffit Hassan; Markku Miettinen; Liqiang Xi; Mark Raffeld; Lisa T Uechi; Xinmin Li; Ruihong Wang; Haobin Chen; Chuong D Hoang; Raphael Bueno; David S Schrump
Journal:  J Thorac Oncol       Date:  2020-09-11       Impact factor: 15.609

8.  UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4.

Authors:  Heng He; Chunsik Lee; Jong Kyong Kim
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

Review 9.  Targeting the SET and RING-associated (SRA) domain of ubiquitin-like, PHD and ring finger-containing 1 (UHRF1) for anti-cancer drug development.

Authors:  Debasis Patnaik; Pierre-Olivier Estève; Sriharsa Pradhan
Journal:  Oncotarget       Date:  2018-05-25

10.  Silencing UHRF1 Enhances Radiosensitivity of Esophageal Squamous Cell Carcinoma by Inhibiting the PI3K/Akt/mTOR Signaling Pathway.

Authors:  Beina Hui; Shupei Pan; Shaomin Che; Yuchen Sun; Yanli Yan; Jia Guo; Tuotuo Gong; Juan Ren; Xiaozhi Zhang
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.